{"id":333611,"date":"2026-10-30T15:05:44","date_gmt":"2026-10-30T09:35:44","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=333611"},"modified":"2026-10-30T15:05:44","modified_gmt":"2026-10-30T09:35:44","slug":"oleochemical-additives-maker-contract-drug-development-and-manufacturing-company-and-generic-drug-maker-stocks-roadmap-trailmap-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/oleochemical-additives-maker-contract-drug-development-and-manufacturing-company-and-generic-drug-maker-stocks-roadmap-trailmap-list\/","title":{"rendered":"3 Oleochemical Additives Maker, Contract Drug Development and Manufacturing Company and Generic Drug Maker Stocks With a Strong Future Roadmap: Fine Organic Industries, Anthem Biosciences and Alembic Pharmaceuticals"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Fine Organic Industries, Anthem Biosciences and Alembic Pharmaceuticals: ROE of 11.9% to 19.4% and FY22 to FY26 revenue CAGR of 6.8% to 15.5%. Prices as of 29 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three oleochemical, contract pharma and generic stocks to watch are Fine Organic Industries, Anthem Biosciences and Alembic Pharmaceuticals. Their return on equity ranges from 11.9% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.8% to 15.5%. Anthem Biosciences leads on both return on equity at 19.4% and revenue growth at 15.5% a year. Prices are based on the 29 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Oleochemical, contract pharma and generic stocks let investors follow companies that serve a growing part of the Indian economy. Fine Organic Industries, Anthem Biosciences and Alembic Pharmaceuticals cover an oleochemical additives maker, a contract drug development and manufacturing company and a generic drug maker.<\/p>\n<p>This list covers three oleochemical, contract pharma and generic stocks with complete current figures: Fine Organic Industries, Anthem Biosciences and Alembic Pharmaceuticals. Every figure comes from the latest reported financials and the 29 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=oleochemical-additives-maker-contract-drug-development-and-manufacturing-company-and-generic-drug-maker-stocks-roadmap-trailmap-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/oleochemical-additives-maker-contract-drug-development-and-manufacturing-company-and-generic-drug-maker-stocks-roadmap-trailmap-list\/#What_Are_Oleochemical_Contract_Pharma_and_Generic_Stocks\" title=\"What Are Oleochemical, Contract Pharma and Generic Stocks?\">What Are Oleochemical, Contract Pharma and Generic Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/oleochemical-additives-maker-contract-drug-development-and-manufacturing-company-and-generic-drug-maker-stocks-roadmap-trailmap-list\/#Oleochemical_Contract_Pharma_and_Generic_Stocks_at_a_Glance\" title=\"Oleochemical, Contract Pharma and Generic Stocks at a Glance\">Oleochemical, Contract Pharma and Generic Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/oleochemical-additives-maker-contract-drug-development-and-manufacturing-company-and-generic-drug-maker-stocks-roadmap-trailmap-list\/#Why_Do_Oleochemical_Contract_Pharma_and_Generic_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Oleochemical, Contract Pharma and Generic Stocks Have a Strong Roadmap in India?\">Why Do Oleochemical, Contract Pharma and Generic Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/oleochemical-additives-maker-contract-drug-development-and-manufacturing-company-and-generic-drug-maker-stocks-roadmap-trailmap-list\/#Why_Fine_Organic_Industries_Features_Among_These_Oleochemical_Contract_Pharma_and_Generic_Stocks\" title=\"Why Fine Organic Industries Features Among These Oleochemical, Contract Pharma and Generic Stocks\">Why Fine Organic Industries Features Among These Oleochemical, Contract Pharma and Generic Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/oleochemical-additives-maker-contract-drug-development-and-manufacturing-company-and-generic-drug-maker-stocks-roadmap-trailmap-list\/#Why_Anthem_Biosciences_Features_Among_These_Oleochemical_Contract_Pharma_and_Generic_Stocks\" title=\"Why Anthem Biosciences Features Among These Oleochemical, Contract Pharma and Generic Stocks\">Why Anthem Biosciences Features Among These Oleochemical, Contract Pharma and Generic Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/oleochemical-additives-maker-contract-drug-development-and-manufacturing-company-and-generic-drug-maker-stocks-roadmap-trailmap-list\/#Why_Alembic_Pharmaceuticals_Features_Among_These_Oleochemical_Contract_Pharma_and_Generic_Stocks\" title=\"Why Alembic Pharmaceuticals Features Among These Oleochemical, Contract Pharma and Generic Stocks\">Why Alembic Pharmaceuticals Features Among These Oleochemical, Contract Pharma and Generic Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/oleochemical-additives-maker-contract-drug-development-and-manufacturing-company-and-generic-drug-maker-stocks-roadmap-trailmap-list\/#Fine_Organic_Industries_vs_Anthem_Biosciences_vs_Alembic_Pharmaceuticals_on_Key_Financials\" title=\"Fine Organic Industries vs Anthem Biosciences vs Alembic Pharmaceuticals on Key Financials\">Fine Organic Industries vs Anthem Biosciences vs Alembic Pharmaceuticals on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/oleochemical-additives-maker-contract-drug-development-and-manufacturing-company-and-generic-drug-maker-stocks-roadmap-trailmap-list\/#Key_Risks_to_Check_Before_Investing_in_Oleochemical_Contract_Pharma_and_Generic_Stocks\" title=\"Key Risks to Check Before Investing in Oleochemical, Contract Pharma and Generic Stocks\">Key Risks to Check Before Investing in Oleochemical, Contract Pharma and Generic Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/oleochemical-additives-maker-contract-drug-development-and-manufacturing-company-and-generic-drug-maker-stocks-roadmap-trailmap-list\/#Final_Thoughts_on_Oleochemical_Contract_Pharma_and_Generic_Stocks\" title=\"Final Thoughts on Oleochemical, Contract Pharma and Generic Stocks\">Final Thoughts on Oleochemical, Contract Pharma and Generic Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/oleochemical-additives-maker-contract-drug-development-and-manufacturing-company-and-generic-drug-maker-stocks-roadmap-trailmap-list\/#What_are_oleochemical_contract_pharma_and_generic_stocks\" title=\"What are oleochemical, contract pharma and generic stocks?\">What are oleochemical, contract pharma and generic stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/oleochemical-additives-maker-contract-drug-development-and-manufacturing-company-and-generic-drug-maker-stocks-roadmap-trailmap-list\/#Which_oleochemical_contract_pharma_and_generic_stocks_are_covered_in_this_list\" title=\"Which oleochemical, contract pharma and generic stocks are covered in this list?\">Which oleochemical, contract pharma and generic stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/oleochemical-additives-maker-contract-drug-development-and-manufacturing-company-and-generic-drug-maker-stocks-roadmap-trailmap-list\/#Why_do_oleochemical_contract_pharma_and_generic_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do oleochemical, contract pharma and generic stocks have a strong future roadmap in India?\">Why do oleochemical, contract pharma and generic stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/oleochemical-additives-maker-contract-drug-development-and-manufacturing-company-and-generic-drug-maker-stocks-roadmap-trailmap-list\/#How_has_Fine_Organic_Industries_performed_financially\" title=\"How has Fine Organic Industries performed financially?\">How has Fine Organic Industries performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/oleochemical-additives-maker-contract-drug-development-and-manufacturing-company-and-generic-drug-maker-stocks-roadmap-trailmap-list\/#How_has_Anthem_Biosciences_performed_financially\" title=\"How has Anthem Biosciences performed financially?\">How has Anthem Biosciences performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/oleochemical-additives-maker-contract-drug-development-and-manufacturing-company-and-generic-drug-maker-stocks-roadmap-trailmap-list\/#How_has_Alembic_Pharmaceuticals_performed_financially\" title=\"How has Alembic Pharmaceuticals performed financially?\">How has Alembic Pharmaceuticals performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/oleochemical-additives-maker-contract-drug-development-and-manufacturing-company-and-generic-drug-maker-stocks-roadmap-trailmap-list\/#What_risks_should_investors_check_before_buying_oleochemical_contract_pharma_and_generic_stocks\" title=\"What risks should investors check before buying oleochemical, contract pharma and generic stocks?\">What risks should investors check before buying oleochemical, contract pharma and generic stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/oleochemical-additives-maker-contract-drug-development-and-manufacturing-company-and-generic-drug-maker-stocks-roadmap-trailmap-list\/#Is_this_list_of_oleochemical_contract_pharma_and_generic_stocks_investment_advice\" title=\"Is this list of oleochemical, contract pharma and generic stocks investment advice?\">Is this list of oleochemical, contract pharma and generic stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Oleochemical_Contract_Pharma_and_Generic_Stocks\"><\/span><strong>What Are Oleochemical, Contract Pharma and Generic Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Oleochemical, contract pharma and generic stocks are listed companies that make additives for food, plastics and cosmetics, serve global pharma and biotech firms with discovery, development and manufacturing and sell generics, branded medicines and active ingredients. Their earnings depend on orders, approvals and product mix.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Oleochemical_Contract_Pharma_and_Generic_Stocks_at_a_Glance\"><\/span><strong>Oleochemical, Contract Pharma and Generic Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/fineorg\/fine-organic-industries-ltd-share-price-today\">Fine Organic Industries<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,152<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16,561<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">37.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">35.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.03<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/anthem\/anthem-biosciences-ltd-share-price-today\">Anthem Biosciences<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">830.15<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">45,546<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">79.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.02<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/aplltd\/alembic-pharmaceuticals-ltd-share-price-today\">Alembic Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">794.85<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14,914<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">21.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">35.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.25<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Alembic Pharmaceuticals trades at a P\/E below the industry P\/E, while Fine Organic Industries and Anthem Biosciences trade above it, which reflects the growth the market already expects. Readers comparing oleochemical, contract pharma and generic stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Oleochemical_Contract_Pharma_and_Generic_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Oleochemical, Contract Pharma and Generic Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Oleochemical, contract pharma and generic stocks have a strong roadmap in India because global drug makers outsourcing more work, wider use of specialty additives and steady medicine demand keep widening the market for these specialty companies.<\/p>\n<ul>\n<li><strong>Outsourcing.<\/strong> Global pharma partners with Indian developers.<\/li>\n<li><strong>Specialty additives.<\/strong> Niche products support pricing strength.<\/li>\n<li><strong>Generic demand.<\/strong> Medicines bring repeat orders.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Fine_Organic_Industries_Features_Among_These_Oleochemical_Contract_Pharma_and_Generic_Stocks\"><\/span><strong>Why Fine Organic Industries Features Among These Oleochemical, Contract Pharma and Generic Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the oleochemical, contract pharma and generic stocks on this list, Fine Organic Industries is a leading maker of oleochemical-based additives used in food, plastics, cosmetics and coatings, selling to customers in India and overseas.<\/p>\n<p>In the June 2026 quarter, revenue grew 14.4% year on year to Rs 718 crore, while net profit rose 18.0% to Rs 138 crore. Revenue rose from Rs 1,909 crore in FY22 to Rs 2,482 crore in FY26, a compound annual growth rate of 6.8%.<\/p>\n<p>Net profit grew from Rs 260 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 12.6%. The company has a return on equity of 15.7%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 16,561 crore. The stock trades at a P\/E of 37.8, above the industry P\/E of 35.1.<\/p>\n<p><strong>Roadmap:<\/strong> The company holds a strong position in additives for plastics and food products and is adding capacity to meet export demand. A large net cash position and low debt give flexibility to invest in new product lines.<\/p>\n<p><strong>What to watch:<\/strong> Monitor raw material prices, export demand and the pace of new capacity addition.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Anthem_Biosciences_Features_Among_These_Oleochemical_Contract_Pharma_and_Generic_Stocks\"><\/span><strong>Why Anthem Biosciences Features Among These Oleochemical, Contract Pharma and Generic Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the specialty and contract pharma shares on this list, Anthem Biosciences is a research-driven contract development and manufacturing organisation that serves global pharma and biotech customers with discovery, development and manufacturing services.<\/p>\n<p>The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P\/E of 79.1, above the industry P\/E of 36.0.<\/p>\n<p>Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%.<\/p>\n<p><strong>Roadmap:<\/strong> The company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.<\/p>\n<p><strong>What to watch:<\/strong> Monitor the order pipeline from global customers and the ramp-up of newer manufacturing capacity.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Alembic_Pharmaceuticals_Features_Among_These_Oleochemical_Contract_Pharma_and_Generic_Stocks\"><\/span><strong>Why Alembic Pharmaceuticals Features Among These Oleochemical, Contract Pharma and Generic Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Alembic Pharmaceuticals is a Vadodara-based drug maker that sells generic formulations in the United States, branded medicines in India and active ingredients to other manufacturers.<\/p>\n<p>Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%.<\/p>\n<p>In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P\/E of 21.6, below the industry P\/E of 35.7.<\/p>\n<p><strong>Roadmap:<\/strong> The company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.<\/p>\n<p><strong>What to watch:<\/strong> Follow new approvals in the United States, the pace of complex generic launches and domestic growth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Fine_Organic_Industries_vs_Anthem_Biosciences_vs_Alembic_Pharmaceuticals_on_Key_Financials\"><\/span><strong>Fine Organic Industries vs Anthem Biosciences vs Alembic Pharmaceuticals on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three oleochemical, contract pharma and generic stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Fine Organic Industries<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,909<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,482<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">6.8%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">417<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Anthem Biosciences<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,280<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,280<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.5%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">592<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">26.0%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Alembic Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,356<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7,399<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8.4%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">671<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9.1%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Anthem Biosciences posts the highest return on equity in this group at 19.4%. Alembic Pharmaceuticals has the largest FY26 revenue at Rs 7,399 crore, and Anthem Biosciences shows the fastest revenue growth with a 15.5% compound annual rate. A useful habit with oleochemical, contract pharma and generic stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Oleochemical_Contract_Pharma_and_Generic_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Oleochemical, Contract Pharma and Generic Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these oleochemical, contract pharma and generic stocks, the main points are: Long-term specialty and contract pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<li><strong>Currency moves.<\/strong> Export earnings move with the rupee.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter oleochemical, contract pharma and generic stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Oleochemical_Contract_Pharma_and_Generic_Stocks\"><\/span><strong>Final Thoughts on Oleochemical, Contract Pharma and Generic Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Oleochemical, contract pharma and generic stocks reward investors who follow demand trends, order books and margins together. Fine Organic Industries, Anthem Biosciences and Alembic Pharmaceuticals each have a clear plan to grow. Based on the 29 October 2026 close, Fine Organic Industries trades at Rs 5,152, Anthem Biosciences at Rs 830.15 and Alembic Pharmaceuticals at Rs 794.85. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these oleochemical, contract pharma and generic stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track oleochemical, contract pharma and generic stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_oleochemical_contract_pharma_and_generic_stocks\"><\/span><strong>What are oleochemical, contract pharma and generic stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Oleochemical, contract pharma and generic stocks are listed companies that make additives for food, plastics and cosmetics, serve global pharma and biotech firms with discovery, development and manufacturing and sell generics, branded medicines and active ingredients. Their earnings depend on orders, approvals and product mix. This list looks at three of them, Fine Organic Industries, Anthem Biosciences and Alembic Pharmaceuticals, using reported FY22 to FY26 financials and the 29 October 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_oleochemical_contract_pharma_and_generic_stocks_are_covered_in_this_list\"><\/span><strong>Which oleochemical, contract pharma and generic stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Fine Organic Industries, Anthem Biosciences and Alembic Pharmaceuticals. Based on the 29 October 2026 close, Fine Organic Industries traded at Rs 5,152, Anthem Biosciences at Rs 830.15 and Alembic Pharmaceuticals at Rs 794.85. Their return on equity ranges from 11.9% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.8% to 15.5%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_oleochemical_contract_pharma_and_generic_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do oleochemical, contract pharma and generic stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Oleochemical, contract pharma and generic stocks have a strong roadmap in India because global drug makers outsourcing more work, wider use of specialty additives and steady medicine demand keep widening the market for these specialty companies. The main drivers are as follows. Outsourcing. Global pharma partners with Indian developers. Specialty additives. Niche products support pricing strength. Generic demand. Medicines bring repeat orders. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Fine_Organic_Industries_performed_financially\"><\/span><strong>How has Fine Organic Industries performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 1,909 crore in FY22 to Rs 2,482 crore in FY26, a compound annual growth rate of 6.8%. Net profit grew from Rs 260 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 12.6%. In the June 2026 quarter, revenue grew 14.4% year on year to Rs 718 crore, while net profit rose 18.0% to Rs 138 crore. The company has a return on equity of 15.7%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 16,561 crore. The stock trades at a P\/E of 37.8, above the industry P\/E of 35.1. Looking ahead, the company holds a strong position in additives for plastics and food products and is adding capacity to meet export demand. A large net cash position and low debt give flexibility to invest in new product lines.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Anthem_Biosciences_performed_financially\"><\/span><strong>How has Anthem Biosciences performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P\/E of 79.1, above the industry P\/E of 36.0. Looking ahead, the company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Alembic_Pharmaceuticals_performed_financially\"><\/span><strong>How has Alembic Pharmaceuticals performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P\/E of 21.6, below the industry P\/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_oleochemical_contract_pharma_and_generic_stocks\"><\/span><strong>What risks should investors check before buying oleochemical, contract pharma and generic stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying oleochemical, contract pharma and generic stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_oleochemical_contract_pharma_and_generic_stocks_investment_advice\"><\/span><strong>Is this list of oleochemical, contract pharma and generic stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 29 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are oleochemical, contract pharma and generic stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Oleochemical, contract pharma and generic stocks are listed companies that make additives for food, plastics and cosmetics, serve global pharma and biotech firms with discovery, development and manufacturing and sell generics, branded medicines and active ingredients. Their earnings depend on orders, approvals and product mix. This list looks at three of them, Fine Organic Industries, Anthem Biosciences and Alembic Pharmaceuticals, using reported FY22 to FY26 financials and the 29 October 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which oleochemical, contract pharma and generic stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Fine Organic Industries, Anthem Biosciences and Alembic Pharmaceuticals. Based on the 29 October 2026 close, Fine Organic Industries traded at Rs 5,152, Anthem Biosciences at Rs 830.15 and Alembic Pharmaceuticals at Rs 794.85. Their return on equity ranges from 11.9% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.8% to 15.5%.\"}},{\"@type\":\"Question\",\"name\":\"Why do oleochemical, contract pharma and generic stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Oleochemical, contract pharma and generic stocks have a strong roadmap in India because global drug makers outsourcing more work, wider use of specialty additives and steady medicine demand keep widening the market for these specialty companies. The main drivers are as follows. Outsourcing. Global pharma partners with Indian developers. Specialty additives. Niche products support pricing strength. Generic demand. Medicines bring repeat orders. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Fine Organic Industries performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 1,909 crore in FY22 to Rs 2,482 crore in FY26, a compound annual growth rate of 6.8%. Net profit grew from Rs 260 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 12.6%. In the June 2026 quarter, revenue grew 14.4% year on year to Rs 718 crore, while net profit rose 18.0% to Rs 138 crore. The company has a return on equity of 15.7%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 16,561 crore. The stock trades at a P\/E of 37.8, above the industry P\/E of 35.1. Looking ahead, the company holds a strong position in additives for plastics and food products and is adding capacity to meet export demand. A large net cash position and low debt give flexibility to invest in new product lines.\"}},{\"@type\":\"Question\",\"name\":\"How has Anthem Biosciences performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P\/E of 79.1, above the industry P\/E of 36.0. Looking ahead, the company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.\"}},{\"@type\":\"Question\",\"name\":\"How has Alembic Pharmaceuticals performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P\/E of 21.6, below the industry P\/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying oleochemical, contract pharma and generic stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying oleochemical, contract pharma and generic stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of oleochemical, contract pharma and generic stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 29 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Oleochemical, Contract Pharma and Generic Stocks with a strong future roadmap: Fine Organic Industries, Anthem Biosciences and Alembic Pharmaceuticals. Compare price, valuation, return on equity and revenue growth as of 28 October 2026.<\/p>\n","protected":false},"author":35,"featured_media":333610,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[10050,9113,3803,18690,18688,14108,18030,18689],"class_list":["post-333611","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-alembic-pharmaceuticals","tag-anthem-biosciences","tag-best-stocks","tag-chemical-and-contract-pharma-stocks","tag-contract-pharma-and-generic-stocks","tag-fine-organic-industries","tag-oleochemical","tag-specialty-and-contract-pharma-shares"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["333610"],"rank_math_title":["Oleochemical Additive, Contract Pharma and Generic Stocks"],"rank_math_description":["Compare 3 oleochemical, contract pharma and generic stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 28 Oct 2026."],"rank_math_focus_keyword":["oleochemical, contract pharma and generic stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-oleochemical-additives-maker-contract-drug-development-and-manufacturing.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/333611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=333611"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/333611\/revisions"}],"predecessor-version":[{"id":333612,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/333611\/revisions\/333612"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/333610"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=333611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=333611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=333611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}